Literature DB >> 25319540

Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.

Maoqing Dong1, Ashton M Vattelana1, Polo C-H Lam1, Andrew J Orry1, Ruben Abagyan1, Arthur Christopoulos1, Patrick M Sexton1, David R Haines1, Laurence J Miller2.   

Abstract

Understanding the molecular basis of ligand binding to receptors provides insights useful for rational drug design. This work describes development of a new antagonist radioligand of the type 1 cholecystokinin receptor (CCK1R), (2-fluorophenyl)-2,3-dihydro-3-[(3-isoquinolinylcarbonyl)amino]-6-methoxy-2-oxo-l-H-indole-3-propanoate (T-0632), and exploration of the molecular basis of its binding. This radioligand bound specifically with high affinity within an allosteric pocket of CCK1R. T-0632 fully inhibited binding and action of CCK at this receptor, while exhibiting no saturable binding to the closely related type 2 cholecystokinin receptor (CCK2R). Chimeric CCK1R/CCK2R constructs were used to explore the molecular basis of T-0632 binding. Exchanging exonic regions revealed the functional importance of CCK1R exon 3, extending from the bottom of transmembrane segment (TM) 3 to the top of TM5, including portions of the intramembranous pocket as well as the second extracellular loop region (ECL2). However, CCK1R mutants in which each residue facing the pocket was changed to that present in CCK2R had no negative impact on T-0632 binding. Extending the chimeric approach to ECL2 established the importance of its C-terminal region, and site-directed mutagenesis of each nonconserved residue in this region revealed the importance of Ser(208) at the top of TM5. A molecular model of T-0632-occupied CCK1R was consistent with these experimental determinants, also identifying Met(121) in TM3 and Arg(336) in TM6 as important. Although these residues are conserved in CCK2R, mutating them had a distinct impact on the two closely related receptors, suggesting differential orientation. This establishes the molecular basis of binding of a highly selective nonpeptidyl allosteric antagonist of CCK1R, illustrating differences in docking that extend beyond determinants attributable to distinct residues lining the intramembranous pocket in the two receptor subtypes.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25319540      PMCID: PMC4279081          DOI: 10.1124/mol.114.095430

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  47 in total

1.  ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI). Interview by Wendy A. Warr.

Authors:  John Overington
Journal:  J Comput Aided Mol Des       Date:  2009-02-05       Impact factor: 3.686

2.  Relationship between native and recombinant cholecystokinin receptors: role of differential glycosylation.

Authors:  E M Hadac; D V Ghanekar; E L Holicky; D I Pinon; R W Dougherty; L J Miller
Journal:  Pancreas       Date:  1996-08       Impact factor: 3.327

3.  Molecular basis of secretin docking to its intact receptor using multiple photolabile probes distributed throughout the pharmacophore.

Authors:  Maoqing Dong; Polo C-H Lam; Delia I Pinon; Keiko Hosohata; Andrew Orry; Patrick M Sexton; Ruben Abagyan; Laurence J Miller
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

4.  First intracellular loop of the human cholecystokinin-A receptor is essential for cyclic AMP signaling in transfected HEK-293 cells.

Authors:  V Wu; M Yang; J A McRoberts; J Ren; R Seensalu; N Zeng; M Dagrag; M Birnbaumer; J H Walsh
Journal:  J Biol Chem       Date:  1997-04-04       Impact factor: 5.157

5.  Molecular basis and species specificity of high affinity binding of vasoactive intestinal polypeptide by the rat secretin receptor.

Authors:  M H Holtmann; E M Hadac; C D Ulrich; L J Miller
Journal:  J Pharmacol Exp Ther       Date:  1996-11       Impact factor: 4.030

6.  Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro.

Authors:  H Taniguchi; N Yazaki; T Endo; M Nagasaki
Journal:  Eur J Pharmacol       Date:  1996-05-23       Impact factor: 4.432

7.  Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling.

Authors:  Maoqing Dong; Polo C-H Lam; Delia I Pinon; Ruben Abagyan; Laurence J Miller
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

8.  Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.

Authors:  Eyup Akgün; Meike Körner; Fan Gao; Kaleeckal G Harikumar; Beatrice Waser; Jean Claude Reubi; Philip S Portoghese; Laurence J Miller
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

9.  GPCR 3D homology models for ligand screening: lessons learned from blind predictions of adenosine A2a receptor complex.

Authors:  Vsevolod Katritch; Manuel Rueda; Polo Chun-Hung Lam; Mark Yeager; Ruben Abagyan
Journal:  Proteins       Date:  2010-01

10.  Helix movement is coupled to displacement of the second extracellular loop in rhodopsin activation.

Authors:  Shivani Ahuja; Viktor Hornak; Elsa C Y Yan; Natalie Syrett; Joseph A Goncalves; Amiram Hirshfeld; Martine Ziliox; Thomas P Sakmar; Mordechai Sheves; Philip J Reeves; Steven O Smith; Markus Eilers
Journal:  Nat Struct Mol Biol       Date:  2009-02-01       Impact factor: 15.369

View more
  7 in total

Review 1.  Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target.

Authors:  Laurence J Miller; Aditya J Desai
Journal:  Trends Endocrinol Metab       Date:  2016-05-04       Impact factor: 12.015

2.  Impact of ursodeoxycholic acid on a CCK1R cholesterol-binding site may contribute to its positive effects in digestive function.

Authors:  Aditya J Desai; Maoqing Dong; Kaleeckal G Harikumar; Laurence J Miller
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-07-02       Impact factor: 4.052

Review 3.  Cholecystokinin-induced satiety, a key gut servomechanism that is affected by the membrane microenvironment of this receptor.

Authors:  A J Desai; M Dong; K G Harikumar; L J Miller
Journal:  Int J Obes Suppl       Date:  2016-11-16

4.  The Nonpeptide Agonist MK-5046 Functions As an Allosteric Agonist for the Bombesin Receptor Subtype-3.

Authors:  Irene Ramos-Alvarez; Tatiana Iordanskaia; Samuel A Mantey; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2022-05-29       Impact factor: 4.402

5.  Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.

Authors:  Aditya J Desai; Polo C H Lam; Andrew Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; Laurence J Miller
Journal:  J Med Chem       Date:  2015-12-10       Impact factor: 7.446

6.  Permanent Photodynamic Cholecystokinin 1 Receptor Activation: Dimer-to-Monomer Conversion.

Authors:  Wen Yi Jiang; Yuan Li; Zhi Ying Li; Zong Jie Cui
Journal:  Cell Mol Neurobiol       Date:  2018-06-04       Impact factor: 5.046

7.  Sulfated Cholecystokinin-8 Promotes CD36-Mediated Fatty Acid Uptake into Primary Mouse Duodenal Enterocytes.

Authors:  Claire Demenis; John McLaughlin; Craig P Smith
Journal:  Front Physiol       Date:  2017-09-01       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.